New remarkable case
study just added to conference!
Day 1- 12:15 Activating Mutations in the EGF
Receptor underlie the
Clinical Response to Gefitinib
Dr. Jeffrey Settleman, Associate Professor,
Medicine,
Harvard Medical School -MGH Cancer Center
Scheduled
immediately following CHI's GPCRs:
From Orphan to Blockbuster, June 7-8, 2004, Boston,
Massachusetts
Overview
Protein kinases play an essential
role in many signaling pathways, and therefore have the
potential to contribute to diseases ranging from cancer and
inflammation to diabetes and cardiovascular disorders, not to
mention cell growth, survival and many other biological
functions. Recent investigations reveal that there are over 500
human kinases, making them the most populated class of druggable
targets. Identification of kinase specificity and functional
validation of kinases as targets has been a challenge, but
innovative approaches have been developed to address these
issues. This conference provides useful insight into strategies
that are being employed in structure-based design and screening
approaches, as well as questions of compound selectivity between
kinases. Case studies of drug development will provide
additional lessons that will aid the audience in their research
efforts.
SCIENTIFIC ADVISORS
Dr. Paul Lyne, AstraZeneca R & D
Dr. Mark Namchuk, Vertex Pharmaceuticals, Inc.
Dr. Chris Vlahos, Lilly Research Laboratories
SPEAKERS AND CHAIRPERSONS
Dr. Geoffrey
Alms,Upstate Inc.
Dr. Mikhail V. Blagosklonny, New York Medical College
Dr.Sean Buchanan, Senior Director, Bioinformatics Structural GenomiX, Inc.
Dr. Charles Cho, Scripps Research Institute
Dr. Claudio Chuaqui, Biogen Idec
Dr. Seth P. Cohen, Caliper Life Sciences
Ms. Geeta Devgan, Yale University
Dr. David J. Diller, Pharmacopeia, Inc.
Ms. Roxanne Duan, OriGene Technologies, Inc.
Dr. David Dudley, Pfizer Global Research & Development
Dr. Doriano Fabbro, Novartis Institutes of Biomedical Research
Dr. Erding Hu, GlaxoSmithKline Pharmaceuticals
Dr. Ulrike Korf, German Cancer Research Center (DKFZ),
Dr. Mitchell Kostich, Schering-Plough Research Institute
Dr. Michael Milburn, Plexxikon Inc.
Dr. Esteban Masuda, Director, Immunology, Rigel Pharmaceuticals
Dr. Steven Pelech, Kinexus Bioinformatics Corporation
Dr. Simon Plyte, Pharmacia - Gruppo Pfizer
Dr. Kumkum Saxena, Vertex Pharmaceuticals
Dr. William R. Sellers, Harvard Medical School, Dana-Farber
Cancer Institute
Dr. Jeffrey Settleman, Associate Professor, Medicine, Harvard Medical School-MGH Cancer Center
Dr. William Shakespeare, ARIAD Pharmaceuticals
Dr. Chris J. Vlahos, Lilly Research Laboratories
|
FUNCTIONAL UNDERSTANDING OF KINASES |
- Census and
Classification of Human Protein Kinases
- Tracking the
Kineome by Multiblotting with Antibodies and Peptide
Antibody Mimetics
- Kinases In Bulk:
Gene Families As System Biology Tools For Functional
Studies
- Global Analysis of
Yeast Protein Kinases using Protein Chips
- Protein Micro
Arrays as a Tool to Identify Novel Protein-Protein
Interactions
|
|
DRUG DEVELOPMENT:
SCREENING STRATEGIES |
- Screens for Novel
Small Molecule and cDNA Inhibitors of PI3K/Akt Signaling
- High Content
Screening Based on Imaging of Translocation of a Key
Transcription Factor
- Evaluating Kinase
Compound Selectivity: Testing a Panel of Public
Compounds
- Scaffold Based Drug
Discovery against Kinase Targets
- Kinases, Homology
Models, and High Throughput Docking
|
|
LUNCHEON TECHNOLOGY WORKSHOP: MICROFLUIDICS |
- High Quality
Screening From Targets to Leads
|
|
DRUG DEVELOPMENT: DESIGN |
- Application of
Knowledge Constraints to Virtual Screening for Kinase
Inhibitors
- Chemometrical
Analysis of Ephrin-Eph Kinase Interactions using GRID/CPCA
Approach
- Strategies for the
Cloning, Expression and Purification of Enzymatically
Active
- Protein Kinases
from Insect Cells
|
|
APPLICATIONS |
- Development of Non-ATP
Competitive MEK Inhibitors
- Rho Kinase Inhibitors
as Potential Therapeutic Agents for Cardiovascular
Diseases
- Discovery and
Development of a Novel Class of Mast Cell Activation
Inhibitors for Allergy and Asthma
- Cancer Drug Discovery
Involving Key Protein Kinases
- Targeting Protein
Kinases in Cancer Therapy
- Selective Combinations
of Anticancer Agents: Toward Novel Use of Kinase
Inhibitors
- FLT3: A Kinase of
Considerable Therapeutic Interest
- Structure-guided Drug
Discovery for Protein Kinases using Fragment-based Lead
Identification/Lead Optimization
|
Call for Sponsors and Exhibitors
Showcase your company's expertise, brand your solutions and
develop revenue opportunities with qualified decision-makers by
becoming an exhibitor or sponsor at GPCRs and Kinases.
Sponsorship opportunities include: technology workshop
presentations, poster competitions, refreshment breaks and
networking receptions just to name a few. We also have
high-visibility items such as conference padfolios and badge
lanyards, which will brand your company name and logo.
For more information on exhibiting
and sponsoring, please contact Arnie Wolfson at 781-972-5431, or
awolfson@healthtech.com
|
